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OBJECTIVES This study sought to evaluate the diagnostic potential of contrast-enhanced transthoracic
echocardiography (CE-TTE) during adenosine infusion, a noninvasive method for evaluating
coronary flow reserve (CFR), in detecting restenosis after successful percutaneous translumi-
nal coronary angioplasty (PTCA).
BACKGROUND Restenosis is the most important limitation of PTCA, and CFR can be impaired in patients
with angiographically documented significant coronary stenosis.
METHODS We performed 6  2 months of follow-up of 53 patients after successful elective PTCA in
the left anterior descending coronary artery (LAD). Coronary angiography was performed at
the end of the planned follow-up period or even before, if clinically indicated. Thus, of the
53 patients, a total of 63 angiographic studies were performed; CE-TTE assessment of CFR
was achieved before each of the 63 angiographic studies.
RESULTS Coronary angiography revealed the presence of restenosis (defined as 50% stenosis at a
previous PTCA site) in 32 angiographic examinations (group A) and no coronary restenosis
in the remaining 31 examinations (group B). Coronary flow reserve was significantly reduced
in group A compared with group B (1.65  0.5 vs. 3.17  0.8, p  0.001). A noninvasive
CFR value 2 was 93% specific and 78% sensitive for detecting significant restenosis, with
positive and negative diagnostic accuracies of 92% and 80%, respectively.
CONCLUSIONS Noninvasive CFR assessment by CE-TTE is an accurate method of monitoring significant
restenosis in the LAD when following up patients submitted to elective PTCA. (J Am Coll
Cardiol 2002;40:896–903) © 2002 by the American College of Cardiology Foundation
Since its clinical introduction, percutaneous transluminal
coronary angioplasty (PTCA) has shown major limitations
as far as the incidence of restenosis (1,2), usually occurring
within the first months after the procedure (3). Although
angiography is commonly considered as the “reference
standard” in defining restenosis, it is inadequate in moni-
toring vessel anatomy and assessing the functional impor-
tance of eventual restenosis because of its invasiveness and
exclusive morphologic investigation (4).
Coronary flow reserve (CFR) is impaired in the presence
of significant coronary stenosis (5) and recovers after suc-
cessful PTCA (6). Thus, CFR assessed with the intracoro-
nary Doppler flow wire (DFW) is used to evaluate PTCA
results (7). However, its clinical use is limited in follow-up
studies because of its invasiveness and the consequent
immediate CFR assessment after PTCA. Recently, nonin-
vasive evaluation of CFR obtained by phase-contrast mag-
netic resonance imaging (MRI) has been proposed to
identify flow-limiting stenosis in patients with clinical signs
of ischemia after PTCA (8). However, MRI assessment of
CFR, although noninvasive and therefore ideal for long-
term monitoring, has limited clinical applicability because it
is expensive and not generally available.
We have recently developed a new noninvasive technique
based on contrast-enhanced transthoracic echocardiography
(CE-TTE) for the assessment of CFR in the left anterior
coronary descending artery (LAD) (9). Coronary flow
reserve obtained by this new method correlates with coro-
nary anatomy severity (10) and intracoronary DFW (11,12).
The aim of this study was to assess the diagnostic
potential of noninvasive evaluation of CFR obtained by
CE-TTE in monitoring significant restenosis in the LAD
of follow-up patients submitted to elective PTCA.
METHODS
Study group. Fifty-three patients (35 men and 18 women;
mean age 62  9 years [range 30 to 80]) with coronary
artery disease submitted to elective PTCA of the LAD were
scheduled for an angiographic control study at an average of
six months (6  2 months) after PTCA (Table 1). Exclu-
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sion criteria included patients with a previous myocardial
infarction in the LAD territory, grade II or III atrioventric-
ular block, severe chronic obstructive pulmonary disease,
and bronchospasm.
Follow-up protocol. All patients underwent diagnostic
coronary angiography at the end of the planned follow-up
period or before, if clinically indicated (occurrence of new,
typical angina and evidence of ischemia on routine nonin-
vasive cardiac imaging tests). The day before each of the
angiographic studies, noninvasive assessment of CFR was
performed by means of CE-TTE. During follow-up, a new
PTCA procedure, at a previous PTCA site, was performed
if clinically indicated. If a new PTCA was performed, a new
follow-up study was started. The study was approved by the
institutional ethics committee, and all patients were in-
formed of the purpose and nature of the study and they
provided written, informed consent.
Contrast-enhanced transthoracic Doppler echocar-
diography. Echocardiography was performed for CFR
evaluation using CE-TTE before and after adenosine infu-
sion, as previously described (9–11), with an ultrasound
system (Sequoia C256, Acuson, Mountain View, Califor-
nia) connected to a broad-band transducer with second
harmonic capability (3V2c). All studies were continuously
recorded on 0.5-in. (1.27-cm) S-VHS videotape. Briefly,
CFR was measured in the distal portion of the LAD, first
obtaining a modified foreshortened two-chamber view or, if
a distal LAD flow recording was not feasible, using a low
parasternal short-axis view of the base of the heart, as
previously described (9–11). If the angle between color flow
and the Doppler beam was 20°, angle correction was
performed using the software package included in the
software unit. Administration of the contrast agent (Levo-
vist, Schering AG, Berlin, Germany) (13) was performed
both before and during adenosine intravenous administra-
tion. The echocardiographic contrast agent was adminis-
tered by infusion, using a devoted infusion pump (IVAC
P4000 anesthesia syringe pump, Medical System, Hamp-
shire, UK) with a concentration of 300 mg/ml and an
infusion rate ranging from 0.5 to 2.0 ml/min, according to
the quality and entity of the Doppler signal enhancement
achieved.
Coronary flow velocity reserve assessment. All patients
had Doppler recordings of the LAD with adenosine infu-
sion at a rate of 0.14 mg/kg per min for 5 min. All patients
had continuous heart rate and electrocardiographic moni-
toring, as well as blood pressure recording at baseline,
during adenosine infusion, and at recovery. Cardiac medi-
cations were interrupted before adenosine, although all
medications or methylxanthine-containing substances were
withheld 48 h before the study. Beverages containing
methylxanthine substances (e.g., coke, tea, coffee) were
restricted for 24 h before the study. Coronary flow reserve in
the LAD was calculated by one experienced echocardiog-
rapher (Dr. Montisci) performing the test, with no knowl-
edge of the angiographic and clinical data, as the ratio of
hyperemic to basal diastolic flow velocity (for each variable,
the highest of three cycles was averaged) (10). Patients
studied were unselected, including those with a large body
mass.
Observer variabilities. Interobserver and intraobserver
variabilities in assessing CFR have been previously assessed
in our laboratory (9); they were 3.2% and 3.0%, respectively.
Coronary angiography. Coronary angiography was per-
formed using the standard Judkins’ method with the femoral
or radial artery approach, as indicated. Coronary stenosis
was assessed using orthogonal angiographic projections by
one investigator who was unaware of the CE-TTE results
(Dr. Ruscazio). Quantitative angiographic analyses were
performed with a computer-assisted analysis system (Med-
con Ltd., Tel Aviv, Israel) or with an automatic system for
biplane quantitative coronary arteriography from 35-mm
films (14). Coronary restenosis in the LAD was defined as
50% lumen diameter narrowing at a previous PTCA site
on the follow-up angiogram.
Statistical analysis. Continuous variables are expressed as
the mean value  SD. Differences in the absolute value and
in the percent increase in velocity were assessed by the
paired or unpaired t test, as appropriate. Sensitivity and
specificity were calculated in the usual manner.
RESULTS
A total of 63 angiographic studies were performed in the
group of 53 patients considered in this study. Of these 63
angiographic studies, only 16 were performed before the
initially scheduled time, because they were clinically indi-
cated, whereas the other 47 were obtained at the established
end of follow-up (6  2 months after PTCA). Coronary
angiography revealed significant restenosis (lumen narrow-
ing 50%) in 32 angiographic examinations (group A) and
no coronary restenosis in the remaining 31 examinations
(group B).
Evaluation of CFR. Pulsed-wave Doppler tracings suit-
able for CFR evaluation were obtained in 50 patients in the
distal portion of the LAD and in the remaining 3 patients
in the mid portion of the vessel. In all patients, CE-TTE
studies were well tolerated. Figures 1 and 2 show two
different clinical cases, both correctly identified by CE-
TTE. In the first patient, coronary angiography six months
after PTCA showed the absence of restenosis; in the second
Abbreviations and Acronyms
CE-TTE  contrast-enhanced transthoracic
echocardiography
CFR  coronary flow reserve
DFW  Doppler flow wire
LAD  left anterior descending coronary artery
MRI  magnetic resonance imaging
PTCA  percutaneous transluminal coronary
angioplasty
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1 F 59 LAD 4 74% 1.58 Yes 7 69% 2.0 No
2 M 69 LAD, Cx, Dg 7 75% 1.0 Yes
3 F 59 LAD, RCA 6 31% 3.3 Yes
4 F 54 LAD 1 24% 3.2 Yes 8 76% 1.58 Yes
5 M 47 LAD 7 30% 2.47 No
6 M 71 LAD 8 19% 4.3 No
7 F 70 LAD 2 27% 3.3 Yes 7 59% 2.5 Yes
8 F 80 LAD 6 29% 3.57 No
9 M 51 LAD, Cx, RCA 5 21% 4.87 No
10 F 68 LAD 2 21% 3.24 Yes 8 35% 2.5 Yes
11 M 69 LAD, Om, RCA 6 60% 2.4 No
12 F 62 LAD 3 30% 2.7 Yes
13 M 51 LAD 10 68% 1.53 Yes 7 17% 3.2 No
14 M 67 LAD, Cx, RCA 6 43% 1.5 No
15 M 56 LAD, Cx, DP 6 34% 3.9 No
16 M 49 LAD 6 40% 2.96 No
17 F 61 LAD, RCA 6 70% 1 Yes 7 66% 1.8 Yes
18 M 62 LAD, RCA 5 63% 1.6 No
19 M 66 LAD, RCA 7 38% 2.84 No
20 F 72 LAD 6 68% 1.8 Yes
21 M 67 LAD, Cx 7 26% 3.59 No
22 F 62 LAD 6 37% 2.78 Yes 5 10% 4.89 No
23 M 62 LAD, Om, RCA 8 23% 3.09 No
24 M 38 LAD, Om, RCA 8 22% 4.26 No
25 M 45 LAD 5 84% 1 Yes
26 F 75 LAD, RCA 6 65% 1.5 Yes 6 42% 2.23 No
27 M 51 LAD 5 72% 1.1 Yes
28 F 72 LAD, Cx 4 80% 1.6 Yes
29 M 71 LAD, Cx 7 36% 2.9 Yes
30 M 63 LAD 6 29% 2.7 No
31 M 75 LAD, Cx, RCA 2 70% 1.87 Yes
32 M 60 LAD 7 57% 1.8 Yes
33 M 60 LAD 5 95% 1.3 Yes 5 95% 1.73 Yes
34 F 69 LAD, Dg 6 38% 3.73 Yes
35 F 74 LAD, Cx 6 7% 3.47 No
36 M 67 LAD, Cx 6 62% 1.8 No
37 F 70 LAD, Dg 6 63% 1.9 Yes
38 M 55 LAD, Dg 5 55% 1.78 Yes 2 74% 2.1 Yes
39 M 50 LAD, RCA 6 54% 2.86 No
40 F 54 LAD, RCA 6 44% 2.88 No
41 M 54 LAD, Cx, RCA 6 72% 2.25 Yes
42 M 57 LAD, Cx 6 54% 2.2 Yes
43 M 81 LAD, RCA 6 68% 0.82 Yes
44 M 58 LAD, Cx 8 22% 1.6 No
45 M 66 LAD, Cx, RCA 6 44% 3.5 No
46 M 64 LAD, Om 6 71% 0.87 No
47 F 60 LAD, Cx, RCA 4 25% 2.6 Yes
48 M 67 LAD, Dg 5 74% 1.15 Yes
49 F 62 LAD, Dg 2 33% 2.8 Yes
50 M 71 LAD 6 95% 1.6 Yes
51 M 69 LAD, Dg 4 61% 1.06 No
52 M 50 LAD 6 40% 3.09 No
53 M 73 LAD, Cx, RCA 2 57% 1.82 Yes
*Coronary vessel(s) with stenosis 50. †New follow-up started in the same patient for restenosis detection and new PTCA on LAD. All patients had PTCA and stenting of
the LAD.
CE-TTE  contrast-enhanced transthoracic echocardiography; CFR  coronary flow reserve; Cx  circumflex artery; Dg  diagonal branch; DP  posterior descending
coronary artery; LAD  left anterior descending coronary artery; Om  obtuse marginal branch; Pt.  patient; PTCA  percutaneous transluminal coronary angioplasty;
QCA  quantitative coronary angiography; RCA  right coronary artery.
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Figure 1. Absence of left anterior descending coronary artery (LAD) restenosis after percutaneous transluminal coronary angioplasty (PTCA) at six-month follow-up angiography in Patient no. 8 (see Table
1). Severe LAD stenosis (upper left panel) was successfully treated with PTCA and stent placement (upper middle panel). At the end of follow-up, angiography showed the absence of restenosis (upper
right panel). Coronary flow velocity assessed by contrast-enhanced transthoracic echocardiography on the day before angiography increased from baseline (lower left panel) to post-adenosine administration














patient, coronary angiography performed five months after
PTCA, before the end of follow-up, because of angina
reoccurrence, showed the presence of coronary restenosis at
a previous PTCA site.
In the basal state, peak diastolic velocity in the LAD was
not significantly different between group A (37  12.6
cm/s) and group B (33  13.7 cm/s). However, CFR, as
shown in Figure 3, was significantly impaired in group A
compared with group B (1.65  0.5 vs. 3.17  0.8, p 
0.001). Severe impairment of CFR (2) was found in most
patients in group A (25/32 [78%]), but in only two patients
in group B (2/31 [6%], p  0.001). Sensitivity, specificity,
and positive and negative diagnostic accuracies of noninva-
sive assessment of CFR in detecting coronary restenosis
were 78%, 93%, 92%, and 80%, respectively. If, instead of
severe CFR impairment, moderate impairment of CFR
(2.5) was considered as a marker of restenosis, then
sensitivity increased to 94%, with only a modest reduction in
specificity (87%).
Clinical findings and angiographic and coronary flow
results. Coronary angiography was performed before the
established follow-up end in 16 patients: in 15 because of
new clinical signs of angina (9 of these patients had LAD
restenosis; 8 of these had an abnormal CFR, whereas the
remaining patient had a normal CFR value, although in the
low range [2.2]; in 6 of these patients, a new PTCA was
performed; 1 patient was submitted to CABG, while the
remaining 2 refused a new PTCA. Of the other 6 patients,
all had normal CFR, without coronary restenosis). In the
remaining patient, earlier coronary angiography was per-
formed because an abnormal exercise stress test was found at
four-month follow-up along with a reduction of CFR (1.06)
and coronary restenosis of 61% at quantitative coronary
angiography, but with no sign of angina. Among the 47
patients submitted to angiography at the scheduled end of
the follow-up protocol, CFR was normal in 27 and abnor-
mal in 20. Twenty-one of the 27 patients with normal CFR
showed no significant restenosis at coronary angiography; 8
of these 27 patients had angina. Among the 20 patients with
impaired CFR at the end of the scheduled follow-up, 18
had significant coronary restenosis (15 of these 18 patients
had angina).
DISCUSSION
This study demonstrates that noninvasive CFR assessment,
obtained by means of CE-TTE, is an extremely feasible and
highly accurate tool for detection of LAD restenosis after
PTCA.
The use of PTCA as treatment of significant hemody-
namic coronary stenosis has consistently increased over the
past years. Treatment of LAD stenosis by PTCA is of
particular clinical relevance, because its presence is an
important independent risk factor of death, with an in-
creased mortality rate at three years (15). However, coronary
restenosis can develop early after PTCA (3), with an
incidence varying from 12% to 60%, according to different
series of patients (2,16,17). Most cases of restenosis usually
occur within six months of PTCA (17), and about one-third
of these develop in the absence of chest pain (18,19). Thus,
clinical symptoms are considered inaccurate predictors of
restenosis. Furthermore, coronary flow monitoring after
PTCA is of particular clinical relevance in a specific subset
of patients—for example, in diabetics in whom restenosis, as
recently demonstrated, is a major determinant of long-term
mortality (20). Because of the relevant incidence of LAD
disease (21) and its important clinical impact, as well as the
recurrent risk of restenosis after PTCA, a noninvasive, easily
performable, and very accurate method capable of identify-
ing LAD restenosis after PTCA could be extremely impor-
tant from the clinical point of view.
Currently used diagnostic techniques have relatively lim-
ited diagnostic potential in this context, because they only
provide indirect signs of restenosis. In fact, noninvasive
diagnostic tests commonly used in the follow-up of patients
submitted to PTCA, such as exercise stress electrocardiog-
raphy (22), stress echocardiography (23) and nuclear perfu-
sion studies (24), have a relatively poor sensitivity and low
predictive value, especially in patients with single-vessel
disease (25).
Doppler assessment of coronary restenosis after PTCA.
Contrast-enhanced transthoracic echocardiography is a
new, feasible, and reliable tool for noninvasive measurement
of CFR (9–12,26–28).
In previous reports from other laboratories (12,26–28), as
well as from our own (9–11), feasibility ranged from 78% to
100% and was higher when contrast enhancement was
employed (9–11). Hozumi et al. (12) and Caiati et al. (11)
have shown that agreement between CE-TTE–derived and
DFW-derived CFR was close, with an excellent correlation
between invasive and noninvasive methods. Diagnostic
accuracy of CE-TTE is comparable to that observed using
Figure 3. Bar graph indicating coronary flow reserve (CFR) values for
angiographic studies showing or not showing post-percutaneous translu-
minal coronary angioplasty restenosis (groups A and B). The mean
values SD are also shown. LAD left anterior descending coronary artery.
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Figure 2. Restenosis in the LAD five months after PTCA in Patient no. 27 (see Table 1). In the upper left panel, tight coronary stenosis (arrow) was successfully treated by PTCA and stent placement (upper
middle panel). Coronary angiography performed at five months, before the scheduled end of follow-up, because of angina recurrence, revealed 72% intrastent stenosis of the proximal LAD (upper right panel).
Coronary flow velocity assessed by CE-TTE on the day before angiography did not increase from baseline (lower left panel) to post-adenosine administration (lower right panel), showing severe impairment














much more expensive tools for CFR assessment, such as
phase-contrast MRI (8). Our study has shown that CE-
TTE appears to have great potential usefulness in the
clinical follow-up of patients submitted to PTCA of the
LAD, because of its noninvasiveness and therefore, easy
repeatability. In our series of patients, some false-positive
and false-negative studies occurred, as in other studies in
which CFR was used for the same purpose (7,8). These
discrepancies (limited in our study to 9 of our 63 CE-TTE
angiographic comparisons: 7 false-positive and 2 false-
negative) can be easily explained by the well-known limited
relationship existing between functional and anatomic esti-
mates of stenosis severity (4), especially when intermediate-
severity restenosis is present (29), as found in most of this
group of patients (Table 1).
Advantages of CE-TTE– derived CFR assessment in
PTCA-treated follow-up patients. The importance of
CFR in assessing short- and long-term outcomes in a
clinical follow-up of patients after PTCA has already been
stressed by the Doppler Endpoints Balloon Angioplasty
Trial Europe (DEBATE) study (30). This study assessed
the predictive value of early post-PTCA CFR assessment
with respect to the clinical outcome. In the DEBATE series
of patients, a CFR value of 2.5, with a residual percent
diameter stenosis 35%, was considered the best indicator
of a low incidence of recurrence of symptoms at one- and
six-month follow-up; however, the predictive values of this
combined variable to detect restenosis were modest (10% vs.
19% and 23% vs. 47%, respectively). A possible explanation
for this poor predictive power is that measurements were
performed immediately after PTCA, when the CFR value
can be temporarily impaired because of transient microcir-
culatory dysfunction. This temporary, reversible dysfunction
can be explained by several possible mechanisms: release of
microemboli (31), neurally mediated vasoconstriction (32)
or microcirculatory vasospasm (33). Thus, the early CFR
measurements, along with the impossibility of serially re-
peating CFR measurements, because of the invasiveness of
the DFW procedure, could account for the low predictive
value of DFW in the long-term follow-up of DEBATE
patients. Because it is noninvasive and easily repeatable,
CE-TTE allows serial CFR assessment not only soon after
the PTCA procedure but also, more importantly, at a
temporal distance from it, when the restoration of micro-
vascular function allows a CFR estimate that is more closely
related to the epicardial vessel’s anatomic condition.
Study limitations. This method has several limitations.
First of all, at present, CE-TTE–derived CFR evaluation
can only be achieved in the LAD, leaving the circumflex and
right coronary artery territories not suitable for CE-TTE
study. Second, CFR assessment can be invalidated if mea-
surements are performed at the coronary stenosis site (13) or
if the LAD is totally occluded and flow in the LAD
branches is falsely considered as flow in the main coronary
artery. However, accurate LAD mapping and preliminary
knowledge of the patient’s previous coronary anatomy,
which are possible in this particular clinical context, can
circumvent these limitations. Third, in this study, contrast
enhancement was used for improving the feasibility of
coronary flow recording. Nevertheless, as reported by other
groups (12,28), adequate recording of LAD coronary flow
and flow reserve can be successfully achieved, although with
a lower feasibility and in the absence of concomitant
infusion of a contrast agent. Finally, because the aim of this
study was not to compare the diagnostic accuracy of this
new method with other diagnostic techniques, established
diagnostic procedures during patient follow-up were not
generally performed in all patients; instead, they were
scheduled according to the clinical picture of the patient and
on the referring physician’s request.
Conclusions. Contrast-enhanced transthoracic evaluation
of CFR in the LAD is a new, feasible, and accurate tool for
the detection of significant LAD stenosis, as well as for the
identification of post-PTCA LAD restenosis. The results of
this study confirm and extend previous data reported from
our group on the diagnostic potential of this new approach
(9–11). To investigate, in more depth, this diagnostic tool’s
potential and to compare it with established diagnostic
procedures, larger studies are needed. These future studies
should be aimed at detecting the diagnostic potential in a
larger population, as well at defining the long-term clinical
impact of noninvasively detected post-PTCA restenosis in
the absence of clinical signs of ischemia.
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